Stay updated with breaking news from Graybug Vision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Graybug Vision, Inc. (NASDAQ:GRAY – Get Rating) have received a consensus recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average twelve-month price target […]
Graybug Vision, Inc. (NASDAQ:GRAY – Get Rating) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 75,100 shares, a decrease of 19.6% from the February 28th total of 93,400 shares. Based on an average trading volume of 89,300 shares, the short-interest ratio is presently 0.8 days. […]
/PRNewswire/ -- DelveInsight's Food Allergy Market Insights report proffers a detailed comprehension of Food Allergy market size by treatment, epidemiology,...
- The recent launch of Aimmune's Palforzia has paved the way for other key players to invest in the food allergy treatment market landscape. Further, the FDA-approved fast track designation
BALTIMORE, Jan. 20, 2022 -- Graybug Vision, Inc. , a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic... | January 20, 2022